Summary
An estimated 42 million people Worldwide suffer a Head Injury (2.5 million in the EU) that can lead to Mild or Traumatic Brain Injury (TBI). It is a major cause of death and disability, especially in young people, impacting victims and relatives, with significant costs to society, estimated at €33 Billion per annum in Europe alone.
Pre-Hospital and Emergency Care Neuro-Monitoring, including pupillary assessment, is critical in the processes of triage, management and medicating patients to prevent secondary injury to the brain. However, the current method of shining a light into a patient's eyes, in order to estimate pupillary response, is subjective and prone to human error.
The solution is Pupiloscope®, enabling Accurate, Real-time, Quantitative Pupillary Monitoring and Assessment for patients with potentially life threatening head injuries. Pupiloscope is a breakthrough technology that will positively impact clinical pathways as well as patient outcomes. It is quick, simple, and easy to use by Doctors, Nurses and Paramedics of all skill levels. Through collaboration with industry experts, key opinion leaders, engineers and Emergency Care based clinicians, who identified the unmet clinical need, ViVO has successfully developed a functional prototype to TRL 6.
As a direct result of this project, Pupiloscope forecasts sales of €20 Million within 5 years of product launch, improving patient outcomes and reducing both the societal and costs of care in the EU and Globally by an estimated €2 Billion per annum.
This project will seek to develop Pupiloscope into a clinically proven, manufacturing ready and CE approved medical device; incorporating technology finalisation, regulatory approval, health economics, clinical testing and validation, therefore enabling product launch and sales to the EU and Global Emergency Care healthcare markets.
Pre-Hospital and Emergency Care Neuro-Monitoring, including pupillary assessment, is critical in the processes of triage, management and medicating patients to prevent secondary injury to the brain. However, the current method of shining a light into a patient's eyes, in order to estimate pupillary response, is subjective and prone to human error.
The solution is Pupiloscope®, enabling Accurate, Real-time, Quantitative Pupillary Monitoring and Assessment for patients with potentially life threatening head injuries. Pupiloscope is a breakthrough technology that will positively impact clinical pathways as well as patient outcomes. It is quick, simple, and easy to use by Doctors, Nurses and Paramedics of all skill levels. Through collaboration with industry experts, key opinion leaders, engineers and Emergency Care based clinicians, who identified the unmet clinical need, ViVO has successfully developed a functional prototype to TRL 6.
As a direct result of this project, Pupiloscope forecasts sales of €20 Million within 5 years of product launch, improving patient outcomes and reducing both the societal and costs of care in the EU and Globally by an estimated €2 Billion per annum.
This project will seek to develop Pupiloscope into a clinically proven, manufacturing ready and CE approved medical device; incorporating technology finalisation, regulatory approval, health economics, clinical testing and validation, therefore enabling product launch and sales to the EU and Global Emergency Care healthcare markets.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/811499 |
| Start date: | 01-06-2018 |
| End date: | 30-09-2021 |
| Total budget - Public funding: | 1 250 911,25 Euro - 875 637,00 Euro |
Cordis data
Original description
An estimated 42 million people Worldwide suffer a Head Injury (2.5 million in the EU) that can lead to Mild or Traumatic Brain Injury (TBI). It is a major cause of death and disability, especially in young people, impacting victims and relatives, with significant costs to society, estimated at €33 Billion per annum in Europe alone.Pre-Hospital and Emergency Care Neuro-Monitoring, including pupillary assessment, is critical in the processes of triage, management and medicating patients to prevent secondary injury to the brain. However, the current method of shining a light into a patient's eyes, in order to estimate pupillary response, is subjective and prone to human error.
The solution is Pupiloscope®, enabling Accurate, Real-time, Quantitative Pupillary Monitoring and Assessment for patients with potentially life threatening head injuries. Pupiloscope is a breakthrough technology that will positively impact clinical pathways as well as patient outcomes. It is quick, simple, and easy to use by Doctors, Nurses and Paramedics of all skill levels. Through collaboration with industry experts, key opinion leaders, engineers and Emergency Care based clinicians, who identified the unmet clinical need, ViVO has successfully developed a functional prototype to TRL 6.
As a direct result of this project, Pupiloscope forecasts sales of €20 Million within 5 years of product launch, improving patient outcomes and reducing both the societal and costs of care in the EU and Globally by an estimated €2 Billion per annum.
This project will seek to develop Pupiloscope into a clinically proven, manufacturing ready and CE approved medical device; incorporating technology finalisation, regulatory approval, health economics, clinical testing and validation, therefore enabling product launch and sales to the EU and Global Emergency Care healthcare markets.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
